← Back to Home

Personalized ovarian cancer vaccine shows immune activity as 10-person trial reveals antigen presentation challenges

A vaccine tailored to patients’ tumor mutations showed signals of biological activity in a small phase 1 trial, but whether it can delay disease also depends on whether cancer cells retain the ability to be recognized by the immune system.

By SURL BioNews

Giving the immune system a checklist for identifying cancer cells does not necessarily mean it can find its targets. A personalized ovarian cancer vaccine trial observed immune responses and changes in some biomarkers among 10 vaccine recipients, while also revealing an obstacle: even when a vaccine targets tumor mutations, cancer cells may evade recognition because of defects in antigen presentation. The phase 1 study, published October 14 in *Nature Medicine*, provides evidence of the feasibility of manufacturing and administering the vaccine, but is not sufficient to establish efficacy.

The open-label trial, conducted by a team at Dana-Farber Cancer Institute and registered as NCT04024878, evaluated the personalized peptide vaccine NeoVax in combination with the anti-PD-1 antibody nivolumab. The study had two cohorts—newly diagnosed advanced disease and first platinum-sensitive recurrence—and included ovarian, fallopian tube, and primary peritoneal cancers. Of the 10 patients who received the vaccine, 9 were from the recurrent disease cohort. According to trial information from the US National Cancer Institute, feasibility and safety were the primary objectives, while tumor response and progression-free survival were secondary assessments.

NeoVax uses each patient’s tumor mutations to produce synthetic long peptides containing personalized neoantigens, administered with an immune stimulant to help direct immune cells to recognize cancer cells. Patients began vaccination after chemotherapy, receiving an intensive initial series followed by booster doses. Nivolumab was added afterward to relieve some immune suppression. This is a therapeutic vaccine designed to target existing cancer.

However, several hurdles remained between obtaining tumor samples and administering the vaccine. According to CancerNetwork’s summary, 22 patients consented to prescreening, 12 consented to enter the treatment phase, and 10 ultimately received the vaccine, with 9 completing all planned doses. Reasons for not continuing included insufficient samples, disease progression during standard treatment, and personal choice. The study found no unexpected safety signals, and no patients stopped treatment because of toxicity. However, injection-site reactions, muscle pain, chills, and neutropenia occurred, as did grade 3 adverse events.

Biological activity and clinical benefit require a more careful distinction. The report noted that changes over time in CA125 and circulating cell-free DNA suggested biological activity in 6 patients; immune analyses also detected responses to at least one pool of vaccine peptides in 8 patients. These findings support the vaccine’s ability to elicit immune responses, but the finding in 6 patients cannot be interpreted as a 60% objective tumor response rate. Median progression-free survival overall was 3.3 months, and the small sample and lack of a randomized control group prevent any determination of how much additional benefit the vaccine provided.

The study’s analysis of treatment resistance further indicated that vaccine design cannot focus on mutations alone. Among 4 patients whose disease progressed, 2 already had partial loss of HLA genetic information before vaccination. HLA molecules display antigen fragments from within cells to immune cells; if this presentation machinery is impaired, some targets selected for the vaccine may not be effectively displayed. This adds an equally critical question alongside whether a tumor has a mutation: can the tumor still present it?

The next challenge is to translate these immune findings into reproducible disease control. The research team proposed exploring intervention when the residual tumor burden is lower and incorporating HLA and antigen presentation capacity into antigen selection. These approaches still require validation in subsequent trials. For now, the findings clarify both the feasibility of personalized vaccines in ovarian cancer and the reasons they may fail, while stronger clinical evidence is still needed to determine whether they can delay recurrence or extend survival.

References

  1. Broad Institute / Nature Medicine
  2. CancerNetwork
  3. Dana-Farber Cancer Institute
  4. National Cancer Institute